Mauna Kea Technologies Winner of “Best New Technology Solution – Oncology” MedTech Breakthrough Award
Mauna Kea Technologies Winner of “Best New Technology Solution – Oncology” MedTech Breakthrough Award
Prestigious international program recognizes standout digital health & medical technology products and companies
2024 awards program included more than 4,500 nominations from all around the world
Paris and Boston, May 30, 2024 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that it has been selected as the winner of the “Best New Technology Solution - Oncology” award in the 8th annual MedTech Breakthrough Awards program. MedTech Breakthrough is an independent market intelligence organization that recognizes the top companies, technologies, and products in the global digital health and medical technology market, and the 2024 awards program included more than 4,500 nominations from all around the world.
This award recognizes Mauna Kea’s critical role in delivering meaningful MedTech product innovation across a wide range of interventional oncology indications, including gastroenterology, pulmonology and uro-oncology, using its next-generation proprietary in vivo cellular imaging platform, Cellvizio®. The platform allows physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. Physicians are able to use the information provided by Cellvizio® to accurately identify and risk stratify neoplastic tissue and create personalized patient treatment plans, generating significantly more favorable clinical and economic outcomes.
"We are honored to be recognized by MedTech Breakthrough for our newest product innovation and ongoing commitment to advancing MedTech for interventionalists worldwide,” said Sacha Loiseau, Ph.D., Founder, Chairman and Chief Executive Officer of Mauna Kea Technologies. “Cancer remains a leading cause of death worldwide, and many cancers can be cured if detected early and treated effectively. Our next-generation Cellvizio platform continues to push the boundaries of what is possible with real-time cellular imaging in addressing the challenges of diagnosing and treating a wide range of pre-cancerous and cancerous conditions, leading to improved patient outcomes.”
